Sun Pharmaceutical Industries announced interim results from a Phase2 study of interleukin-23 (IL-23) inhibitor ILUMYATM (tildrakizumab-asmn) in patients with activepsoriatic arthritis that was presented in a late-breaking oral presentation at the Annual EuropeanCongress of Rheumatology (EULAR 2019) in Madrid, Spain.
The interimanalysis revealed that over 71 percent of patients treated with ILUMYA™ experienced a 20 percentimprovement in joint and skin symptoms (ACR20), meeting the primary endpoint of the study. Theinterim results showed ILUMYA™ was well tolerated with a low rate of serious treatment-emergentadverse events.
ILUMYA™ is approved in the U.S. for the treatment of adults with moderate-to-severe plaquepsoriasis who are candidates for systemic therapy or phototherapy and is being investigated forpsoriatic arthritis. Psoriatic arthritis, which affects up to 42 percent of people with plaque psoriasis,is an inflammatory condition that impacts both the joints and skin. It is painful, causes fatigue, andcan lead to swelling and stiffness of the joints that may reduce range of motion. If left untreated,this chronic condition can lead to permanent joint damage.